Beacon Capital Management LLC (Tennessee)’s Black Diamond Therapeutics BDTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$28.9K Hold
15,615
﹤0.01% 175
2026
Q1
$33.3K Hold
15,615
0.01% 166
2025
Q4
$37.9K Hold
15,615
0.01% 158
2025
Q3
$59.2K Hold
15,615
0.01% 138
2025
Q2
$38.7K Hold
15,615
0.01% 388
2025
Q1
$24.2K Hold
15,615
﹤0.01% 441
2024
Q4
$33.4K Hold
15,615
﹤0.01% 371
2024
Q3
$67.9K Hold
15,615
0.01% 269
2024
Q2
$72.8K Hold
15,615
0.01% 219
2024
Q1
$79.2K Hold
15,615
0.02% 203
2023
Q4
$44.8K Hold
15,615
0.01% 237
2023
Q3
$78.9K Hold
15,615
0.02% 179
2023
Q2
$78.9K Sell
15,615
-20,000
-56% -$40.8K 0.02% 179
2023
Q1
$67.3K Hold
35,615
0.02% 185
2022
Q4
$64.1K Hold
35,615
0.02% 194
2022
Q3
$88K Buy
35,615
+11,615
+48% +$35.8K 0.03% 151
2022
Q2
$66K Hold
24,000
0.02% 199
2022
Q1
$66K Buy
+24,000
New +$87.6K 0.02% 199

Other funds holding BDTX

Beacon Capital Management LLC (Tennessee)'s BDTX Position: Q2 2026 in Review

Beacon Capital Management LLC (Tennessee) held its Black Diamond Therapeutics (BDTX) position steady in Q2 2026 at 15,615 shares worth $28.9K. The position accounts for ﹤0.01% of the portfolio, ranked #175.

Beacon Capital Management LLC (Tennessee) first reported a position in BDTX in Q1 2022 and has held it in 18 quarters since. The position peaked at $88K in Q3 2022. 13 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Beacon Capital Management LLC (Tennessee) held 15,615 shares of Black Diamond Therapeutics worth $28.9K as of Q2 2026.
  • Beacon Capital Management LLC (Tennessee) left its Black Diamond Therapeutics share count unchanged in Q2 2026.
  • Black Diamond Therapeutics made up ﹤0.01% of Beacon Capital Management LLC (Tennessee)'s portfolio in Q2 2026, its #175 holding.
  • Beacon Capital Management LLC (Tennessee) first reported a position in Black Diamond Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Beacon Capital Management LLC (Tennessee)'s Black Diamond Therapeutics position peaked at $88K in Q3 2022.
  • 13 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Beacon Capital Management LLC (Tennessee)'s 13F filing for Q2 2026, filed 29 Jul 2026.